The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients

Ramiro Núñez; María Teresa Álvarez-Román; Santiago Bonanad; José Ramón González-Porras; Hortensia De La Corte-Rodriguez; Rubén Berrueco; Víctor Jiménez-Yuste

doi:10.1055/s-0042-1757745

TH Open, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · TH Open 2022; 06(04): e365-e377
DOI: 10.1055/s-0042-1757745

Review Article

The Limitations and Unmet Needs of the Five Cornerstones to Guarantee Lifelong Optimization of Prophylaxis in Hemophilia Patients

Authors

Ramiro Núñez^†*

¹Hemophilia Unit, Hospital Universitario Virgen del Rocío, Sevilla, Andalucía, Spain
María Teresa Álvarez-Román^†*

²Department of Hematology and Hemotherapy, La Paz University Hospital-IdiPaz, Madrid, Spain
Santiago Bonanad

³Haemostasis and Thrombosis Unit, Hospital Universitari i Politècnic La Fe, València, Spain
José Ramón González-Porras

⁴Hematology Department, Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (Ibsal), Salamanca, Spain
Hortensia De La Corte-Rodriguez

⁵Department of Physical and Rehabilitation Medicine, La Paz University Hospital-IdiPaz, Madrid, Spain
Rubén Berrueco

⁶Pediatric Hematology Department, Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Barcelona, Spain

⁷Institut de Recerca, Pediàtrica Hospital Sant Joan de Déu de Barcelona (IRP-HSJD0), Barcelona, Spain

⁸Instituto Nacional de Investigación Biomédica en Enfermedades Raras (CIBER ER), Instituto de Salud Carlos III, Madrid, Spain
Víctor Jiménez-Yuste

²Department of Hematology and Hemotherapy, La Paz University Hospital-IdiPaz, Madrid, Spain

Abstract

Prophylaxis to prevent bleeding is highly recommended for hemophilia patients. The development of new drugs and tools for modeling personalized prophylaxis provides the means for people with hemophilia to lead active lives with a quality of life comparable to that of nonhemophilic individuals. The choice of regimens must be made on a highly individual basis. Unfortunately, reference guides neither always concur in their recommendations nor provide directions to cover all possible scenarios. In this review, a group of experts identify the significant limitations and unmet needs of prophylaxis, taking advantage of their clinical experience in the disease, and supported by a rigorous literature update. To perform a more systematic and comprehensive search for gaps, the main cornerstones that influence decisions regarding prophylactic patterns were first identified.

Bleeding phenotype, joint status, physical activity, pharmacokinetics/medication properties, and adherence to treatment were considered as the primary mainstays that should allow physicians guiding prophylaxis to secure the best outcomes. Several challenges identified within each of these topics require urgent attention and agreement. The scores to assess severity of bleeding are not reliable, and lead to no consensus definition of severe bleeding phenotype. The joint status is to be redefined in light of new, more efficient treatments with an agreement to establish one scale as the unique reference for joint health. Further discussion is needed to establish the appropriateness of high-intensity physical activities according to patient profiles, especially because sustaining trough factor levels within the safe range is not always warranted for long periods. Importantly, many physicians do not benefit from the advantages provided by the programs based on population pharmacokinetic models to guide individualized prophylaxis through more efficient and cost-saving strategies. Finally, ensuring correct adherence to long-term treatments may be time-consuming for practitioners, who often have to encourage patients and review complex questionnaires.

In summary, we identify five cornerstones that influence prophylaxis and discuss the main conflicting concerns that challenge the proper long-term management of hemophilia. A consensus exercise is warranted to provide reliable guidelines and maximize benefit from recently developed tools that should notably improve patients' quality of life.

Keywords

hemophilia - prophylaxis - bleeding phenotype - joint status - physical activity - pharmacokinetics - treatment adherence

Volltext

Referenzen

References
1 Srivastava A, Santagostino E, Dougall A. et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1-158
2 Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232 (01) 25-32
3 van den Berg HM, Fischer K, Mauser-Bunschoten EP. et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112 (03) 561-565
4 Feldman BM, Pai M, Rivard GE. et al; Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4 (06) 1228-1236
5 Berntorp E, Astermark J, Björkman S. et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl 1): 1-4
6 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
7 van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11 (05) 438-443
8 van Dijk K, van der Bom JG, Lenting PJ. et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005; 90 (04) 494-498
9 Wyseure T, Mosnier LO, von Drygalski A. Advances and challenges in hemophilic arthropathy. Semin Hematol 2016; 53 (01) 10-19
10 Carcao MD, van den Berg HM, Ljung R, Mancuso ME. PedNet and the Rodin Study Group. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood 2013; 121 (19) 3946-3952 , S1
11 Rendo P, Shafer F, Korth-Bradley JM, Sivamurthy K, Korin J. Factors that influence the bleeding phenotype in severe hemophilic patients. Blood Coagul Fibrinolysis 2013; 24 (07) 683-690
12 Schulman S, Eelde A, Holmström M, Ståhlberg G, Odeberg J, Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6 (07) 1113-1121
13 Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A. subcommittee on factor viii, factor ix and rare coagulation disorders. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost 2018; 16 (10) 2106-2110
14 Tarandovskiy ID, Balandina AN, Kopylov KG. et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res 2013; 131 (06) e274-e280
15 Brecelj J, Bole V, Benedik-Dolnicar M, Grmek M. The co effect of prophylaxis and radiosynovectomy on bleeding episodes in haemophilic synovitis. Haemophilia 2008; 14 (03) 513-517
16 Carcao M, Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia 2010; 16 (Suppl 2): 16-23
17 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
18 Oldenburg J, Zimmermann R, Katsarou O. et al; Cross-sectional MRI study investigators. Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand. Haemophilia 2015; 21 (02) 171-179
19 De la Corte-Rodriguez H, Rodriguez-Merchan EC, Alvarez-Roman MT, Martin-Salces M, Martinoli C, Jimenez-Yuste V. The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia. Expert Rev Hematol 2018; 11 (03) 253-261
20 Kuijlaars IAR, Timmer MA, de Kleijn P, Pisters MF, Fischer K. Monitoring joint health in haemophilia: factors associated with deterioration. Haemophilia 2017; 23 (06) 934-940
21 van Meegeren ME, Roosendaal G, Jansen NW, Lafeber FP, Mastbergen SC. Blood-induced joint damage: the devastating effects of acute joint bleeds versus micro-bleeds. Cartilage 2013; 4 (04) 313-320
22 Ribeiro T, Abad A, Feldman BM. Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1. Res Pract Thromb Haemost 2019; 3 (03) 405-411
23 Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 1993; 30 (3, Suppl 2): 3-6
24 Martinoli C, Della Casa Alberighi O, Di Minno G. et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109 (06) 1170-1179
25 Foppen W, van der Schaaf IC, Beek FJA, Mali WPTM, Fischer K. Diagnostic accuracy of point-of-care ultrasound for evaluation of early blood-induced joint changes: comparison with MRI. Haemophilia 2018; 24 (06) 971-979
26 Poonnoose PM, Hilliard P, Doria AS. et al. Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia 2016; 22 (06) 925-933
27 Lundin B, Manco-Johnson ML, Ignas DM. et al; International Prophylaxis Study Group. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012; 18 (06) 962-970
28 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980; (149) 153-159
29 Poonnoose PM, Manigandan C, Thomas R. et al. Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia 2005; 11 (06) 598-602
30 van Genderen FR, Westers P, Heijnen L. et al. Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12 (01) 36-46
31 Fischer K, Poonnoose P, Dunn AL. et al; Participants of the International Symposium on Outcome Measures in Hemophilic Arthropathy. Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia 2017; 23 (01) 11-24
32 Fischer K, Van den Berg HM, Thomas R. et al. Dose and outcome of care in haemophilia–how do we define cost-effectiveness?. Haemophilia 2004; 10 (Suppl 4): 216-220
33 Feldman BM, Rivard GE, Babyn P. et al. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematol 2018; 5 (06) e252-e260
34 O'Hara J, Walsh S, Camp C. et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes 2018; 16 (01) 84
35 Negrier C, Seuser A, Forsyth A. et al. The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity. Haemophilia 2013; 19 (04) 487-498
36 Mulvany R, Zucker-Levin AR, Jeng M. et al. Effects of a 6-week, individualized, supervised exercise program for people with bleeding disorders and hemophilic arthritis. Phys Ther 2010; 90 (04) 509-526
37 Czepa D, von Mackensen S, Hilberg T. Haemophilia & Exercise Project (HEP): the impact of 1-year sports therapy programme on physical performance in adult haemophilia patients. Haemophilia 2013; 19 (02) 194-199
38 Broderick CR, Herbert RD, Latimer J. et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308 (14) 1452-1459
39 Iorio A, Iserman E, Blanchette V. et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017; 23 (03) e170-e179
40 Anderson A, Forsyth A. Playing it Safe: Bleeding Disorders, Sports and Exercise. New York, NY: National Hemophilia Foundation; 2005. 44.
41 Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 2021; 397 (10274): 630-640
42 Hermans C, Mahlangu J, Booth J. et al. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia 2018; 24 (03) 376-384
43 Lee M, Morfini M, Schulman S, Ingerslev J. The Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis, The design and analysis of pharmacokinetic studies of coagulation factors. ISTH Website. 2001. Available at: https://cdn.ymaws.com/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf
44 Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost 2017; 15 (12) 2461-2465
45 Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A. Subcommittee on Factor VIII, Factor IX, and Rare Bleeding Disorders. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (07) 1437-1441
46 Reininger A. et al. Optimizing prophylaxis: development of an advate PK calculator and dosing medical device based on a Bayesian population PK model: OR07. Haemophilia 2014; •••: 20
47 Iorio A, Keepanasseril A, Foster G. et al; WAPPS-Hemo co-investigator network. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc 2016; 5 (04) e239
48 https://florio.com/es/
49 Mondorf W, Siegmund B, Mahnel R. et al. Haemoassist–a hand-held electronic patient diary for haemophilia home care. Haemophilia 2009; 15 (02) 464-472
50 Delavenne X, Dargaud Y, Ollier E, Négrier C. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: using a limited sampling strategy in patients with severe haemophilia A. Br J Clin Pharmacol 2019; 85 (04) 771-781
51 Megías-Vericat JE, Bonanad S, Haya S. et al. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. Thromb Res 2019; 174: 151-162
52 Stemberger M, Kallenbach F, Schmit E. et al. Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia A patients: a historically controlled observational study. Thromb Haemost 2019; 119 (03) 368-376
53 Nagao A, Yeung CHT, Germini F, Suzuki T. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thromb Res 2019; 173: 79-84
54 Yu JK, Iorio A, Edginton AN. WAPPS co-investigators. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: a scoping review. Res Pract Thromb Haemost 2019; 3 (03) 528-541
55 Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Thromb Res 2017; 157: 58-63
56 Bonanad S, García-Dasí M, Aznar JA. et al. Adherence to prophylaxis in adult patients with severe haemophilia A. Haemophilia 2020; 26 (05) 800-808
57 Torres-Ortuño A, Cuesta-Barriuso R, Nieto-Munuera J, Castiello-Munuera Á, Moreno-Moreno M, López-Pina JA. Haemo-adhaesione: a new measure of adherence for adolescent and adult patients with haemophilia. Patient Prefer Adherence 2020; 14: 455-465
58 Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence 2017; 11: 1677-1686
59 Rayment R, Chalmers E, Forsyth K. et al; British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. Br J Haematol 2020; 190 (05) 684-695
60 Lee Mortensen G, Strand AM, Almén L. Adherence to prophylactic haemophilic treatment in young patients transitioning to adult care: a qualitative review. Haemophilia 2018; 24 (06) 862-872
61 Schrijvers LH, Schuurmans MJ, Fischer K. Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. Haemophilia 2016; 22 (04) 499-506
62 García-Dasí M, Aznar JA, Jiménez-Yuste V. et al. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia 2015; 21 (04) 458-464
63 von Mackensen S, Gringeri A, Siboni SM, Mannucci PM. Italian Association Of Haemophilia Centres (AICE). Health-related quality of life and psychological well-being in elderly patients with haemophilia. Haemophilia 2012; 18 (03) 345-352
64 Takedani H, Solimeno L, Saxena K, Kalweit L, Mathew P. The Haemophilia Joint Visualizer: development of a personalized, interactive, web-based tool to help improve adherence to prophylaxis. Haemophilia 2017; 23 (02) e155-e158
65 Boccalandro EA, Dallari G, Mannucci PM. Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia. Blood Transfus 2019; 17 (05) 385-390
66 Banchev A, Goldmann G, Marquardt N. et al. Impact of telemedicine tools on record keeping and compliance in haemophilia care. Hamostaseologie 2019; 39 (04) 347-354
67 Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med 2020; 382 (18) 1679-1681
68 Álvarez-Román MT, De la Corte-Rodríguez H, Rodríguez-Merchán EC. et al. COVID-19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery. Haemophilia 2021; 27 (01) e137-e139
69 Bauer RJ. NONMEM Tutorial Part II: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol 2019; 8 (08) 538-556